Table 1 Differences in clinicopathological features due to treatments for dyslipidemia
| Â | Treatment for dyslipidemia (n = 938) | Â | |
|---|---|---|---|
| Â | No (n = 744) | Yes (n = 194) | p value |
Age at diagnosis (year) | |||
 ≤61 / >61 | 438 (58.9%) / 306(41.1%) | 47 (24.2%) / 147(75.8%) | p<0.001 |
Menopause | |||
 Pre / Post | 267 (35.9%) / 477(64.1%) | 14 (7.2%) / 180(92.8%) | p<0.001 |
Diabetes | |||
 Negative / Positive | 693 (93.2%) / 51(6.8%) | 142 (73.2%) / 52(26.8%) | p<0.001 |
Tumor size (cm) | |||
 ≤2 / >2 | 422 (56.7%) / 322(43.3%) | 108 (55.7%) / 86(44.3%) | p = 0.808 |
Lymph node status | |||
 Negative / Positive | 492 (66.1%) / 252(33.9%) | 138 (71.1%) / 56(28.9%) | p = 0.199 |
Neoadjuvant chemotherapy | |||
 No / Yes | 663 (89.1%) / 81(10.9%) | 186 (95.9%) / 8(4.1%) | p = 0.004 |
Intrinsic subtype | |||
 Luminal / Luminal-HER / | 513 (68.9%) / 96(12.9%) / | 131 (67.5%) / 23(11.9%) / | p = 0.861 |
 HER2-enruch / TNBC | 51 (6.9) / 84(11.3%) | 16 (8.2) / 24(12.4%) | |